- Home
- BQ vs APLM Comparison
BQ vs APLM Comparison
Compare BQ & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- APLM
- Stock Information
- Founded
- BQ 2008
- APLM 2016
- Country
- BQ China
- APLM United States
- Employees
- BQ N/A
- APLM N/A
- Industry
- BQ Other Specialty Stores
- APLM Blank Checks
- Sector
- BQ Consumer Discretionary
- APLM Finance
- Exchange
- BQ Nasdaq
- APLM Nasdaq
- Market Cap
- BQ 6.0M
- APLM 6.9M
- IPO Year
- BQ 2020
- APLM N/A
- Fundamental
- Price
- BQ $2.19
- APLM $4.89
- Analyst Decision
- BQ
- APLM
- Analyst Count
- BQ 0
- APLM 0
- Target Price
- BQ N/A
- APLM N/A
- AVG Volume (30 Days)
- BQ 78.8K
- APLM 6.9K
- Earning Date
- BQ 05-27-2025
- APLM 04-03-2025
- Dividend Yield
- BQ N/A
- APLM N/A
- EPS Growth
- BQ N/A
- APLM N/A
- EPS
- BQ N/A
- APLM N/A
- Revenue
- BQ $81,208,354.00
- APLM $198,000.00
- Revenue This Year
- BQ N/A
- APLM $415.15
- Revenue Next Year
- BQ N/A
- APLM N/A
- P/E Ratio
- BQ N/A
- APLM N/A
- Revenue Growth
- BQ N/A
- APLM N/A
- 52 Week Low
- BQ $1.62
- APLM $4.71
- 52 Week High
- BQ $7.40
- APLM $42.00
- Technical
- Relative Strength Index (RSI)
- BQ 46.98
- APLM 35.08
- Support Level
- BQ $1.85
- APLM $4.63
- Resistance Level
- BQ $2.82
- APLM $5.45
- Average True Range (ATR)
- BQ 0.26
- APLM 0.54
- MACD
- BQ 0.02
- APLM -0.10
- Stochastic Oscillator
- BQ 26.80
- APLM 16.03
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.